Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 17/20 | 0.51 |
| ▸ | FABP3 | P05413 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120333 | 0.87 | PPARG (0.47) | PPARGFABP3SNCAP2RX7 | |
| SCHEMBL5108668 | 0.82 | PPARG (0.76) | PPARG | |
| SCHEMBL5105830 | 0.79 | PPARG (0.52) | PPARGFABP3 | |
| SCHEMBL5114674 | 0.77 | PPARG (0.54) | PPARG | |
| SCHEMBL5120057 | 0.77 | PPARG (0.51) | PPARGFABP3SNCA | |
| SCHEMBL5113087 | 0.74 | TLR8 (0.42) | PPARGALDH1A1SMN1; SMN2 | |
| SCHEMBL5109148 | 0.74 | PPARG (0.80) | PPARG | |
| SCHEMBL6035849 | 0.73 | MLYCD (0.36) | PPARGFABP3SNCA | |
| SCHEMBL5115463 | 0.73 | PPARG (0.46) | PPARGFABP3SNCA | |
| SCHEMBL5120044 | 0.73 | PPARG (0.41) | PPARGP2RX7ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885FABP3 1103/4885SNCA 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.